All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

An Overview on Bone Tumor

Hangama Smith*

Department of Orthopaedics, University of California, San Francisco, United States

*Corresponding Author:
Hangama Smith
Department of Orthopaedics,
University of California,
San Francisco,
United States

Received:  01-March-2022, Manuscript No. Orthopedics -22- 60113; Editor assigned: 03-March-2022, PreQC No. Orthopedics -22- 60113 (PQ); Reviewed: 15-March-2022, QC No. Orthopedics -22- 60113; Revised: 18-March-2022, Manuscript No. Orthopedics -22- 60113 (R); Published: 25-March-2022, DOI: 10.4172/Orthopedics.6.1.001.

Visit for more related articles at Research & Reviews: Orthopedics


A bone tumour is a noncancerous (benign) or cancerous development of tissue in the bone that is traditionally categorised as noncancerous (benign) (malignant). Cancerous bone tumours are most commonly caused by cancers in other parts of the body, such as the lung, breast, thyroid, kidney, or prostate. Pressure can cause a lump, pain, or neurological signs. A pathologic fracture may accompany a bone tumour. Fatigue, fever, weight loss, anaemia, and nausea are some of the other symptoms that can occur. There are situations when there are no symptoms and the tumour is discovered while exploring another issue.

X-rays and other radiological procedures such as CT scans, MRIs, PET scans, and bone scintigraphy are used to diagnose the condition. A complete blood count, inflammatory indicators, serum electrophoresis, PSA, kidney function, and liver function are examples of blood tests. Bence Jones protein could be tested using urine. A biopsy for histological investigation may be required to confirm the diagnosis.

A non-ossifying fibroma is the most frequent type of bone tumour. After being diagnosed with bone and joint cancer, the average five-year survival rate in the United States is 67 percent. An osteosarcoma in a foot bone unearthed between 1.6 and 1.8 million years ago in South Africa was the first known bone malignancy.

An arm bone tumor

Noncancerous (benign) and cancerous (cancerous) bone tumours are conventionally classed (malignant). Bone tumours and soft tissue tumours have a number of characteristics. The World Health Organization (WHO) altered its classification in 2020. Bone cancers are divided into cartilage tumours, osteogenic tumours, fibrogenic tumours, vascular tumours of bone, osteoclastic giant cell-rich tumours, notochordal tumours, various mesenchymal tumours of bone, and hematopoietic neoplasms of bone in this updated classification.

Bone cancers are divided into two types: "primary tumours" that start in bone or from bone-derived cells and tissues, and "secondary tumours" that originate elsewhere and spread to the skeleton (metastasize). The most prevalent carcinomas that metastasis to bone are those of the prostate, breasts, lungs, thyroid, and kidneys. Primary bone malignancies are believed to be 50 to 100 times more prevalent than secondary malignant bone tumours.

Primary bone tumors

Bone tumours can be classified as either benign or cancerous. The origin of common benign bone tumours can range from neoplastic to developmental to traumatic to infectious to inflammatory. Some benign tumours, such as the osteochondroma, are hamartomas rather than genuine neoplasms. The distal femur and proximal tibia are the most prevalent sites for both benign and malignant primary tumours (around the knee joint). Osteoma, osteoid osteoma, osteochondroma, osteoblastoma, enchondroma, giant cell tumour of bone, and aneurysmal bone cyst are examples of benign bone tumours.

Osteosarcoma, chondrosarcoma, Ewing's sarcoma, fibrosarcoma, and other malignant primary bone tumours are examples. While Malignant Fibrous Histiocytoma (MFH) - now known as "pleomorphic undifferentiated sarcoma" - primary in bone is known to occur on occasion, current paradigms consider MFH a wastebasket diagnosis, and the current trend is to classify these undifferentiated tumours into other tumour classes using specialised studies (i.e. genetic and immunohistochemical tests). Multiple myeloma is a type of hematologic malignancy that starts in the bone marrow and often manifests as one or more bone lesions.

Germ cell tumours, such as teratoma, are common in the midline of the sacrum, the coccyx, or both. Treatment options for sacrococcygeal teratomas are often limited.

Secondary bone tumors

Secondary bone tumours are metastatic lesions that have spread from other organs, most commonly breast, lung, or prostate carcinomas. Primary bone cancers, such as osteosarcoma, can occasionally spread to other bones. Because carcinomas that are broadly metastatic to bone are seldom ever treatable, reliable and valid statistics on the incidence, prevalence, and mortality of malignant bone tumours are difficult to come by, especially in older persons (those over 75 years of age). Biopsies to determine the origin of the tumour are rarely performed in circumstances like this.

Signs and symptoms

The clinical characteristics of a bone tumour vary depending on the type of tumour and which bone is affected. Symptoms and indications are usually caused by the tumor's pressure.

There may be a lump, which may or may not be painful. Pain may worsen as the tumour grows, and it may be worse at night and at rest. With little or no trauma, a bone tumour may show with an unexplained shattered bone. Fatigue, fever, weight loss, anaemia, and nausea are all possible side effects. Neurological signals may be present if the tumour pushes on a nerve. There are situations when there are no symptoms and the tumour is discovered while exploring another issue.